Changes to prothrombin international normalized ratio in patients receiving hemodialysis

被引:4
作者
Maruyama, Noriaki [1 ]
Abe, Masanori [1 ]
Okada, Kazuyoshi [1 ]
Soma, Masayoshi [1 ,2 ]
机构
[1] Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Tokyo 1738610, Japan
[2] Nihon Univ, Sch Med, Dept Internal Med, Div Gen Med, Tokyo 1738610, Japan
关键词
anticoagulation; hemodialysis; international normalized ratio; warfarin; WARFARIN; PHARMACOKINETICS; STROKE; RISK;
D O I
10.5414/CP201779
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The clinical utility of factor Xa inhibitors (xabans) has been demonstrated, but these inhibitors are contraindicated in patients undergoing dialysis therapy. Therefore, warfarin remains the mainstay for oral anticoagulation treatment of patients receiving hemodialysis (HD). Objective: This study investigated the changes in international normalized ratio (INR) during HD treatment of patients receiving warfarin. Methods: Changes in INR and serum albumin levels were determined before (pre-) and after (post-) HD in six consecutive HD sessions. 30 patients (23 males, 7 females; mean age, 72 +/- 8 years) were enrolled, and a total of 180 measurements were performed. Results: Post-HD INR levels were significantly decreased compared with pre-HD levels (2.07 +/- 0.52 to 1.99 +/- 0.50, p < 0.0001), while serum albumin levels were significantly increased post-HD compared with pre-HD (p < 0.0001). There was a significant negative correlation between changes in INR and serum albumin during HD (r = -0.383, p = 0.0002). Conclusion: INR is significantly decreased post-HD compared with pre-HD. Although the therapeutic range of INR differs according to the disease, close monitoring of the degree of anticoagulation in patients receiving warfarin is recommended to minimize the risk of thrombosis and hemorrhagic complications.
引用
收藏
页码:283 / 287
页数:5
相关论文
共 13 条
[1]   DRUG PRESCRIBING IN RENAL-FAILURE - DOSING GUIDELINES FOR ADULTS [J].
BENNETT, WM ;
ARONOFF, GR ;
MORRISON, G ;
GOLPER, TA ;
PULLIAM, J ;
WOLFSON, M ;
SINGER, I .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1983, 3 (03) :155-193
[2]  
BRECKENRIDGE A, 1978, SEMIN HEMATOL, V15, P19
[3]   Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation [J].
Chan, Kevin E. ;
Lazarus, J. Michael ;
Thadhani, Ravi ;
Hakim, Raymond M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10) :2223-2233
[4]  
GANEVAL D, 1986, CLIN NEPHROL, V25, P75
[5]  
KELLY JG, 1979, CLIN PHARMACOKINET, V4, P1, DOI 10.2165/00003088-197904010-00001
[6]   Enhanced anticoagulant effect of warfarin in a patient treated with cloxacillin [J].
Marusic, Srecko ;
Gojo-Tomic, Nives ;
Bacic-Vrca, Vesna ;
Franic, Miljenko .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (06) :431-433
[7]   Drug administration in patients with renal insufficiency - Minimising renal and extrarenal toxicity [J].
Matzke, GR ;
Frye, RF .
DRUG SAFETY, 1997, 16 (03) :205-231
[8]   Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects [J].
McCracken, N. ;
Lahu, G. ;
Bethke, T. D. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (06) :388-396
[9]   Elevated risk of stroke among patients with end-stage renal disease [J].
Seliger, SL ;
Gillen, DL ;
Longstreth, WT ;
Kestenbaum, B ;
Stehman-Breen, CO .
KIDNEY INTERNATIONAL, 2003, 64 (02) :603-609
[10]   CLINICAL PHARMACOKINETIC CONSIDERATIONS IN THE CONTROL OF ORAL ANTICOAGULANT-THERAPY [J].
SHETTY, HGM ;
FENNERTY, AG ;
ROUTLEDGE, PA .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :238-253